Composition for extracting nucleic acid and method for extracting nucleic acid using same

The use of a nucleic acid extraction composition with Brij-58 and anionic surfactants in the composition enhances the sensitivity and accuracy of lung cancer diagnosis by efficiently extracting EV DNA and cfDNA from bronchoalveolar lavage fluid, addressing the limitations of current diagnostic methods and enabling non-invasive genetic testing.

WO2024262933A1PCT designated stage expired Publication Date: 2024-12-26EXOSIGNAL INC

Patent Information

Application Number
PCT/KR2024/008469
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-06-18
Filing Date
2024-06-19
Publication Date
2024-12-26

AI Technical Summary

Technical Problem

Current methods for diagnosing lung cancer, particularly non-small cell lung cancer, are invasive and have low sensitivity due to the challenges of extracting and analyzing genetic mutations from blood and bronchoalveolar lavage fluid, which limits the effectiveness of liquid biopsies.

Method used

A composition for nucleic acid extraction using Brij-58 and an anionic surfactant, along with additional components like guanidine HCL and proteinase K, that allows for the simultaneous extraction of high concentrations of extracellular vesicle DNA (EV DNA) and cell-free DNA (cfDNA) without the need for expensive equipment, enhancing the sensitivity and accuracy of liquid biopsies.

Benefits of technology

This approach enables more accurate and sensitive genetic testing for lung cancer, potentially replacing invasive biopsies by efficiently extracting and analyzing DNA from bronchoalveolar lavage fluid, improving the detection of EGFR mutations and other genetic markers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024008469_26122024_PF_FP_ABST
    Figure KR2024008469_26122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for extracting nucleic acids and a method for extracting nucleic acids using same. The composition for extracting nucleic acids is expected to play a major role in the development of a new liquid biopsy method and the improvement of sensitivity and accuracy of the liquid biopsy method by extracting all of cfDNA and EV DNA present in blood, bronchoalveolar lavage fluid, bronchoalveolar lavage fluid, and the like with high efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for nucleic acid extraction and method for nucleic acid extraction using the same

[0001] The present invention relates to a composition for nucleic acid extraction and a method for extracting nucleic acids using the same.

[0002] Lung cancer is divided into small cell lung cancer and non-small cell lung cancer, with non-small cell lung cancer accounting for 80-90% of cases. Genetic mutations are a major risk factor for non-smokers in non-small cell lung cancer. Representative genes include EGFR, ALK, ROS1, and KRAS.

[0003] Targeted therapy refers to treatments that target only the mutated genes that are the primary cause of cancer development. This approach is particularly well-developed in lung cancer. This type of targeted therapy can extend the average survival rate of cancer patients by two to three times. In particular, molecular diagnostics using DNA are crucial for lung cancer, as they determine the target of targeted therapy based on the presence and type of genetic mutation, or identify genetic mutations that can predict treatment response and drug resistance. This is why molecular diagnostics using DNA, rather than conventional protein or RNA diagnostics, are crucial.

[0004] Lung cancer is diagnosed through a low-dose CT scan, where a lesion is found, and then a percutaneous pulmonary biopsy, an invasive lung tissue examination, is performed. However, this is a very invasive method, causing great pain and anxiety to the patient, and depending on the location and size of the lesion, tissue collection is impossible in approximately 30% of cases.

[0005] To overcome the limitations of existing testing methods, there has been a recent shift toward combining tissue biopsy and liquid biopsy, requiring corresponding technological development. Currently, liquid biopsy using blood is being introduced clinically, but it has the problem of low sensitivity due to the large amount of biopolymers in blood and the small amount of tumor DNA. Bronchoalveolar lavage fluid or bronchial washing fluid is a washing fluid obtained through bronchoscopy and contains not only tumor cells but also cells that make up the tumor microenvironment, extracellular vesicle DNA (EV DNA), and cell-free DNA (cfDNA). In a previous study, EGFR gene mutation testing was performed by extracting DNA from bronchoalveolar lavage fluid and blood, and the sensitivity of EV DNA and cfDNA extracted from bronchoalveolar lavage fluid was confirmed to be higher than that of EV DNA and cfDNA extracted from blood (JY Hur, KY Lee, et al. Molecular Cancer 2018). However, in Korea, there is currently no buffer for DNA extraction from bronchoalveolar lavage fluid or bronchial lavage fluid, or a kit containing the buffer.

[0006] This technology eliminates the need for expensive equipment like ultracentrifuges by eliminating the process of isolating extracellular vesicles from specimens, enabling rapid and efficient extraction of EV DNA and cfDNA simultaneously at high concentrations. Therefore, the development of this technology enhances the accuracy and sensitivity of liquid biopsy, enabling the diagnosis of lung cancer through genetic testing without the need for conventional percutaneous or surgical lung biopsies. It is expected to play a crucial role in genetic testing through liquid biopsy.

[0007] [Prior Art Literature]

[0008] [Patent Document]

[0009] Republic of Korea Patent No. 10-1981398

[0010] Republic of Korea Publication Patent No. 10-2022-0110152

[0011] The purpose of the present invention is to provide a composition for nucleic acid extraction.

[0012] In addition, the present invention aims to provide a nucleic acid extraction kit comprising the above composition.

[0013] In addition, the present invention aims to provide a nucleic acid extraction method using the nucleic acid extraction composition.

[0014] One aspect of the present invention provides a composition for nucleic acid extraction comprising Brij-58 and an anionic surfactant.

[0015] Surfactants are compounds that contain a hydrophilic portion, easily soluble in water, and a hydrophobic portion, easily soluble in oil. They soften the interface between oil and water, facilitating their mixing. Depending on their state of dissociation in water, surfactants are classified as anionic, cationic, amphoteric, and nonionic surfactants.

[0016] “Brij-58” used in the present invention has the chemical formula HO(CH2CH2O)20C 16 H 33 It is called polyethylene glycol hexadecyl ether or polyoxyethylene (20) cetyl ether and is a type of nonionic surfactant that does not ionize in water.

[0017] According to one specific example of the present invention, the Brij-58 may be included in an amount of 10 to 100 mM.

[0018] Specifically, in the nucleic acid extraction composition, Brij-58 may be present at 10 to 100 mM, 15 to 95 mM, 20 to 90 mM, 25 to 85 mM, or 30 to 70 mM.

[0019] The “anionic surfactant” used in the present invention is one that dissolves in water and dissociates anions, and is not limited to any anionic surfactant known in the art.

[0020] According to one specific example of the present invention, the anionic surfactant may be at least one selected from the group consisting of ammonium lauryl sulfate (ALS), sodium lauryl sulfate (SLS), and sodium dodecyl sulfate (SDS).

[0021] Additionally, according to one specific example of the present invention, the anionic surfactant may be included at 0.1 to 10% (v / v).

[0022] Specifically, in the nucleic acid extraction composition, the anionic surfactant may be present in an amount of 0.1 to 10% (v / v), 0.2 to 8% (v / v), 0.4 to 6% (v / v), or 0.6 to 4% (v / v).

[0023] The nucleic acid extraction composition according to the present invention may further include, but is not limited to, guanidine HCL, Tris-HCl, isopropanol, protease K, etc. to improve nucleic acid extraction efficiency.

[0024] According to one specific embodiment of the present invention, the composition may further comprise 1 to 8 M guanidine HCL, 1 to 100 mM Tris-HCl and 10 to 70% (v / v) isopropanol.

[0025] Specifically, in the nucleic acid extraction composition, guanidine HCL may be 1 to 8 M, 2 to 7 M, or 3 to 6 M, Tris-HCl may be 1 to 100 mM, 2 to 80 mM, 4 to 60 mM, 6 to 40 mM, or 8 to 20 mM, and isopropanol may be 10 to 70% (v / v), 15 to 65% (v / v), 20 to 60% (v / v), or 25 to 55% (v / v).

[0026] Additionally, according to one specific example of the present invention, the composition may further comprise 0.1 to 5 mg / mL of proteinase K.

[0027] Specifically, in the nucleic acid extraction composition, proteinase K may be 0.1 to 5 mg / mL, 0.2 to 4.5 mg / mL, 0.4 to 4 mg / mL, or 0.6 to 3.5 mg / mL.

[0028] The nucleic acid extraction composition according to the present invention may be used to extract DNA from at least one specimen known in the art, specifically, from the group consisting of blood, lymph, saliva, urine, feces, pleural fluid, spinal fluid, joint fluid, peritoneal fluid, sputum, bronchial lavage fluid, and bronchoalveolar lavage fluid.

[0029] The "bronchial lavage fluid" or "bronchoalveolar lavage fluid" used in the present invention refers to a liquid obtained by injecting, aspirating, and washing a physiological saline solution into the bronchial tubes or the peripheral portion of the bronchial tubes using a bronchial fibroscope. The bronchial lavage fluid or bronchoalveolar lavage fluid contains cellular components such as macrophages, lymphocytes, and polymorphonuclear leukocytes present in the bronchial tubes or the bronchoalveolar system, as well as physiologically active substances and metabolites present in bronchial cells, and is therefore used for analyzing physiological functions or metabolic abnormalities of the lungs.

[0030] The “nucleic acid extraction composition” used in the present invention refers to a buffer for extracting nucleic acid present in a specimen sample.

[0031] The nucleic acid may be a straight-chain, branched-chain or circular nucleic acid, such as, but not limited to, RNA, particularly messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA), small nuclear RNA (snRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), ribozyme, DNA, cell free DNA (cfDNA), extracellular vesicle DNA (EV DNA), plasmid DNA (pDNA), etc.

[0032] According to one specific example of the present invention, the nucleic acid extraction composition may be for DNA extraction including cfDNA and EV DNA.

[0033]

[0034] Another aspect of the present invention provides a nucleic acid extraction kit comprising the composition.

[0035] The above kit may be provided in the form of a cartridge containing the above-described nucleic acid extraction composition, but is not limited thereto.

[0036] The nucleic acid extraction kit according to the present invention may further include, in addition to the nucleic acid extraction composition, a wash buffer, an elution buffer, etc. necessary for nucleic acid extraction, but is not limited thereto.

[0037]

[0038] Another aspect of the present invention provides a method for extracting nucleic acids comprising the step of contacting the composition with a biological sample isolated from an individual.

[0039] In the above step, the nucleic acid extraction composition described above is reacted with the biological sample, thereby extracting the nucleic acid, particularly DNA, present in the biological sample using the composition.

[0040] The “biological sample” used in the present invention is a biological sample isolated from an individual requiring biological or chemical analysis, and is not limited to any biological sample known in the art.

[0041] According to one specific example of the present invention, the biological sample may be at least one selected from the group consisting of blood, lymph, saliva, urine, feces, pleural fluid, cerebrospinal fluid, joint fluid, peritoneal fluid, sputum, bronchial lavage fluid, and bronchoalveolar lavage fluid.

[0042] The above steps may utilize any extraction method known in the art for nucleic acid extraction without limitation. Examples of nucleic acid extraction methods include, but are not limited to, organic extraction, Chelex extraction, and solid phase extraction.

[0043] The nucleic acid extraction method according to the present invention may further include a step of separating and purifying the extracted nucleic acid after the above step.

[0044] In addition, the nucleic acid extraction method according to the present invention may further include a step of analyzing the extracted, separated or purified nucleic acid after the above step.

[0045] The present invention can utilize any nucleic acid isolation, purification, and analysis method known in the art without limitation. Examples of nucleic acid analysis methods include, but are not limited to, polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), competitive RT-PCR, real-time PCR, nuclease protection assay, in situ hybridization, DNA or RNA microarray, Northern blot, and sequencing.

[0046] The nucleic acid extraction composition according to the present invention is expected to play a major role in the development of a new liquid biopsy method and in improving the sensitivity and accuracy of the liquid biopsy method by extracting cfDNA and EV DNA present in blood, bronchoalveolar lavage fluid, bronchial lavage fluid, etc. with high efficiency.

[0047] FIG. 1 is a graph comparing the DNA concentration and size of bronchoalveolar lavage fluid extracted by nucleic acid extraction compositions 3 and 7 according to one embodiment of the present invention, where (a) shows a small size including 180 bp of cfDNA, and (b) shows a large size including 1,000 bp or more of EV DNA.

[0048] FIG. 2 is a graph comparing the DNA concentration of blood extracted by nucleic acid extraction compositions 1 to 6 according to one embodiment of the present invention.

[0049] FIG. 3 is a graph showing (a) the DNA concentration and (b) the amplification curve Ct value of the internal control (IC) and target gene EGFR of a lung cancer cell line culture medium extracted by nucleic acid extraction compositions 1 to 6 according to one embodiment of the present invention.

[0050] FIG. 4 is a graph showing (a) the DNA concentration and (b) the amplification curve Ct value of the internal control (IC) and the target gene EGFR of bronchoalveolar lavage fluid extracted by nucleic acid extraction compositions 1 to 6 according to one embodiment of the present invention.

[0051] The present invention will be described in more detail below. However, this description is provided merely as an example to aid understanding of the present invention, and the scope of the present invention is not limited by this exemplary description.

[0052]

[0053] Preparation Example 1. Preparation of a composition for nucleic acid extraction

[0054] A composition for nucleic acid extraction was prepared using a nonionic surfactant (Brij-58, NP-40 or Triton x-100) and / or an anionic surfactant (SDS or ALS) to extract nucleic acids from cell line culture fluid or bronchoalveolar lavage fluid.

[0055]

[0056] 1-1. Composition for nucleic acid extraction 1

[0057] It was prepared by sequentially mixing 30.7 mM Brij-58, 4 M guanidine HCL, 10 mM Tris-HCl, and 30% (v / v) isopropanol.

[0058]

[0059] 1-2. Composition for nucleic acid extraction 2

[0060] It was prepared by sequentially mixing 0.8% (v / v) SDS, 4 M guanidine HCL, 10 mM Tris-HCl, and 30% (v / v) isopropanol.

[0061]

[0062] 1-3. Composition for nucleic acid extraction 3

[0063] It was prepared by sequentially mixing 30.7 mM Brij-58, 0.8% (v / v) SDS, 4 M guanidine HCL, 10 mM Tris-HCl, and 30% (v / v) isopropanol.

[0064]

[0065] 1-4. Composition for nucleic acid extraction 4

[0066] It was prepared by sequentially mixing 1% NP-40, 0.8% (v / v) SDS, 4 M guanidine HCL, 10 mM Tris-HCl, and 30% (v / v) isopropanol.

[0067]

[0068] 1-5. Composition for nucleic acid extraction 5

[0069] It was prepared by sequentially mixing 10% Triton x-100, 0.8% (v / v) SDS, 4 M guanidine HCL, 10 mM Tris-HCl, and 30% (v / v) isopropanol.

[0070]

[0071] 1-6. Composition for nucleic acid extraction 6

[0072] It was prepared by sequentially mixing 30.7 mM Brij-58, 0.8% (v / v) ALS, 4 M guanidine HCL, 10 mM Tris-HCl, and 30% (v / v) isopropanol.

[0073]

[0074] 1-7. Composition for nucleic acid extraction 7

[0075] It was prepared by sequentially mixing 20% ​​(v / v) Triton x-100, 0.8% SDS, 6 M guanidine HCL, 10 mM urea, and 10 mM Tris-HCl.

[0076]

[0077] Preparation Example 2. Preparation of lung cancer cell line culture medium, bronchoalveolar lavage fluid, and blood.

[0078] 2-1. Lung cancer cell line culture medium

[0079] The human lung carcinoma cell line PC-9 was cultured in serum-free medium at 37°C with 5% CO2 for 48 h. After 48 h, the cell culture medium was collected in a 50 mL tube and centrifuged at 1,000 × g for 10 min at 4°C. After precipitating cells and cell debris, only the supernatant was transferred to a new tube, and 2 mL of the supernatant was used for DNA extraction.

[0080]

[0081] 2-2. Bronchoalveolar lavage fluid

[0082] The study involved stage 4 non-small cell lung cancer patients. After anesthetizing the oral cavity and pharynx, a flexible bronchoscope was inserted, and sterile normal saline solution heated to 37°C was instilled into the lesion twice, 50 mL each. A total of 100 mL of bronchoalveolar lavage fluid was collected using negative pressure, collected in a tube, and impurities such as mucus were removed using gauze. The bronchoalveolar lavage fluid filtered through the gauze was centrifuged at 1000 × g for 10 minutes at 4°C to separate cells and supernatant, and 2 mL of the supernatant was used for DNA extraction.

[0083]

[0084] 2-3. Blood

[0085] Patients with stage IV non-small cell lung cancer were studied. Blood was collected in EDTA-coated blood collection tubes. To remove blood cells and cellular debris, the blood was centrifuged at 1,600 × g for 10 minutes at room temperature, and only the supernatant was transferred to a new tube, ensuring that the buffy coat was not mixed. The separated supernatant was centrifuged at 16,000 × g for 10 minutes, and 300 μl of the supernatant (plasma) was used to extract DNA.

[0086]

[0087] Experimental Example 1. DNA extraction from bronchoalveolar lavage fluid and measurement of DNA size and concentration.

[0088] DNA was extracted from bronchoalveolar lavage fluid using nucleic acid extraction compositions 3 and 7, and the size and concentration of the DNA were compared.

[0089] Composition 3 for nucleic acid extraction is for extracting total DNA including cfDNA and EV DNA. 2 mL of bronchoalveolar lavage fluid was added to 2 mL of composition 3 for nucleic acid extraction, 67 μl of 20 mg / mL proteinase K was added, and the mixture was dissolved at 55°C for 15 minutes. Afterwards, DNA was adsorbed using magnetic beads (Bioneer, TA-1010-1), washed twice, and eluted to extract DNA.

[0090] Composition 7 for nucleic acid extraction is for extracting EV DNA. First, 2 mL of bronchoalveolar lavage fluid was placed in an ultracentrifuge tube and centrifuged at 200,000 xg at 4℃ for 1 hour to precipitate extracellular vesicles. The supernatant was removed and the precipitate was dissolved with 200 ㎕ of PBS. 200 ㎕ of Composition 7 for nucleic acid extraction and 40 ㎕ of 20 mg / mL proteinase K were added, mixed well, and left to stand at 70℃ for 10 minutes. After the dissolution process, the mixture was transferred to a column (ZYMO RESEARCH, C1104), centrifuged at 8,000 xg for 1 minute, and the supernatant was discarded. After washing twice, 50 ㎕ of distilled water was added to the column and centrifuged at 8,000 xg for 1 minute to extract DNA.

[0091] To measure DNA concentration according to size, cfDNA of 180 bp was used to confirm the distribution and concentration of small-sized DNA using the D1000 ScreenTape System, and EV DNA of 1,000 bp or more was measured using the Genomic ScreenTape System.

[0092] As a result, as shown in Fig. 1, composition 7 for nucleic acid extraction was found to have extracted some EV DNA as a conventional EV DNA extraction composition, but in the case of composition 3 for nucleic acid extraction, it was confirmed that not only EV DNA but also cfDNA was extracted at a higher concentration than composition 7 for nucleic acid extraction.

[0093]

[0094] Experimental Example 2. DNA extraction and DNA concentration measurement from blood

[0095] DNA was extracted from blood using compositions 1 to 6 for nucleic acid extraction, and the DNA concentrations were compared.

[0096] 2 mL of 300 μl of blood sample (plasma) and 1,700 μl of PBS were mixed in 2 mL each of compositions 1 to 6 for nucleic acid extraction, and 67 μl of 20 mg / mL proteinase K were added and dissolved at 55°C for 15 minutes. Afterwards, DNA was extracted through the process of DNA adsorption using magnetic beads (Bioneer, TA-1010-1), washing twice, and elution.

[0097] DNA concentration was measured by mixing 1 μl of DNA and 200 μl of DNA-specific fluorescent dye (Promega, E2670), blocking light for 5 minutes, and then measuring the DNA concentration using a Quantus Fluorometer.

[0098] As a result, as shown in Fig. 2, DNA was extracted from nucleic acid extraction compositions 1 and 3 to 6, and particularly, when nucleic acid extraction compositions 1, 3, and 5 were used, DNA concentrations were high, but the concentration difference between them was not large. On the other hand, when nucleic acid extraction composition 2 was used, no DNA concentration was measured.

[0099]

[0100] Experimental Example 2. EGFR Mutation Gene Analysis

[0101] DNA was extracted from lung cancer cell line culture medium and bronchoalveolar lavage fluid using nucleic acid extraction compositions 1 to 6, and then the EGFR mutant gene was analyzed.

[0102] 2 mL of lung cancer cell line culture medium or bronchoalveolar lavage fluid was added to 2 mL of each of compositions 1 to 6 for nucleic acid extraction, 67 μl of 20 mg / mL proteinase K was added, and the mixture was dissolved at 55°C for 15 minutes. Afterwards, DNA was extracted by adsorbing DNA using magnetic beads (Bioneer, TA-1010-1), washing twice, and elution.

[0103] DNA concentration was measured by mixing 1 μl of DNA and 200 μl of DNA-specific fluorescent dye (Promega, E2670), blocking light for 5 minutes, and then measuring the DNA concentration using a Quantus Fluorometer.

[0104] To verify the performance of EGFR mutation detection, real-time PCR was performed. 5 ㎕ of extracted DNA was added to a PCR tube with 19 ㎕ of PCR mix containing a fluorescent probe that can specifically detect β-actin as an internal control (IC) or EGFR mutant target, a PNA probe that can inhibit the wild-type target, dNTP, MgCl2, etc., and 1 ㎕ of Taq DNA polymerase. Real-time polymerase chain reaction was performed using a CFX-96 PCR machine. The gene amplification reaction conditions were 95℃ for 5 minutes, followed by 35 cycles of 95℃ for 10 seconds, 53℃ for 20 seconds, and 70℃ for 20 seconds to amplify the gene mutation. An amplification curve was plotted using the fluorescence values ​​measured through gene amplification, and the Ct (Cycle threshold) value at which amplification begins was analyzed to confirm the presence or absence of a mutation.

[0105] As a result, as shown in Fig. 3, when nucleic acid extraction compositions 3 and 6 were used for lung cancer cell line culture, the extracted DNA concentration was the highest, and the difference in DNA concentration compared to other nucleic acid extraction compositions was not significant. However, in the PCR results for detecting EGFR mutations, including IC, the target gene detection efficiency was found to be the best when nucleic acid extraction composition 3 was used.

[0106] Also, as shown in Fig. 4, the extracted DNA concentration was the highest when Composition 3 for nucleic acid extraction was used for bronchoalveolar lavage fluid of non-small cell lung cancer patients. In the PCR results for detecting EGFR mutations, including IC, the target gene detection efficiency was found to be the highest when Composition 3 for nucleic acid extraction was used, and the EGFR mutation detection efficiency was also found to be high when Composition 6 for nucleic acid extraction was used.

[0107]

[0108] The present invention has been described above, focusing on preferred embodiments thereof. Those skilled in the art will appreciate that the present invention can be implemented in modified forms without departing from its essential characteristics. Therefore, the disclosed embodiments should be considered illustrative rather than limiting. The scope of the present invention is set forth in the claims, not the foregoing description, and all differences within the scope equivalent thereto should be construed as being encompassed by the present invention.

Claims

1. A composition for nucleic acid extraction comprising Brij-58 and an anionic surfactant.

2. In claim 1, A composition for nucleic acid extraction, wherein the above Brij-58 is included in an amount of 10 to 100 mM.

3. In claim 1, A composition for extracting nucleic acids, wherein the anionic surfactant is at least one selected from the group consisting of ammonium lauryl sulfate (ALS), sodium lauryl sulfate (SLS), and sodium dodecyl sulfate (SDS).

4. In claim 1, A composition for nucleic acid extraction, wherein the anionic surfactant is contained in an amount of 0.1 to 10% (v / v).

5. In claim 1, A composition for nucleic acid extraction, wherein the composition further comprises 1 to 8 M guanidine HCL, 1 to 100 mM Tris-HCl and 10 to 70% (v / v) isopropanol.

6. In claim 1, A composition for nucleic acid extraction, wherein the composition further comprises 0.1 to 5 mg / mL of proteinase K.

7. In claim 1, The composition is a nucleic acid extraction composition for extracting DNA from at least one selected from the group consisting of blood, lymph, saliva, urine, feces, pleural fluid, cerebrospinal fluid, joint fluid, peritoneal fluid, sputum, bronchial washing fluid, and bronchoalveolar washing fluid.

8. A nucleic acid extraction kit comprising the composition of claim 1.

9. A method for extracting nucleic acids, comprising the step of contacting the composition of claim 1 with a biological sample isolated from an individual.

10. In claim 9, A nucleic acid extraction method wherein the biological sample is at least one selected from the group consisting of blood, lymph, saliva, urine, feces, pleural fluid, cerebrospinal fluid, joint fluid, peritoneal fluid, sputum, bronchial washing fluid, and bronchoalveolar washing fluid.

Citation Information

Patent Citations

  • DNA extraction method and extraction device

    KR1019990022612A

  • Cell lysis buffer for extracting DNA and extraction method by using thereof

    KR1020030006505A

  • Methods and Kits for Nucleic Acid Amplification with Conquering Inhibitions of Cell Lysis Chemicals

    KR1020160135887A

  • Method of Isolating Nucleic Acid

    KR1020170027296A

  • KR20190033263A

Cited By

  • DNA EXTRACTION METHOD

    BE1033255B1